ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 trials at the 83 rd American Academy of ...

Sixty-five percent of dermatology providers surveyed agree there is a lack of education and understanding of chronic hand ...

A new survey commissioned by Leo Pharma confirms there’s plenty of room in the market for its chronic hand eczema treatment ...

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 trials at the 83rd American Academy ...

February is the shortest month, but there was still plenty of time for a rush of pharma and biotech hires, including a number ...

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 ...

2 The presentation marks the third consecutive year that LEO Pharma has presented late-breaking data at AAD. Alongside this presentation, new systemic exposure data has also been shared for ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

2 NOT FOR UK USE NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 ...

An Ipsos survey commissioned by LEO Pharma Inc. reveals dermatology providers believe there is a lack of awareness and understanding of chronic hand eczema as a condition separate from eczema ...